---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-005554"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2025-04-25T23:59:59+00:00"
generated_at: "2026-05-23T05:48:48.056265+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Director Mark Stolper to leave board at 2025 annual meeting; board rebalanced

## Summary
- Mark D. Stolper notified Board he will not stand for re-election at 2025 annual meeting; departure not due to any disagreement.
- Stolper will serve until election of directors at 2025 Annual Meeting, then expected to consult through Dec 31, 2026.
- Board decreased authorized directors from 10 to 9, effective upon Stolper's departure.
- Rita A. Karachun reclassified from Class II to Class I; Michael Ryan from Class III to Class II to balance board classes.
- Board now has three Class I, four Class II, and three Class III directors.

## SEC filing metadata
- accession: 0001558370-25-005554
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2025-04-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837025005554/0001558370-25-005554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837025005554/chrs-20250422x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-005554
- JSON: https://secwatch.observer/filing/0001558370-25-005554.json
- Plain text: https://secwatch.observer/filing/0001558370-25-005554.txt

## Key facts
- Executive change
  Mark D. Stolper departed as Director at Coherus Oncology, Inc..
  - Action: not stand for re-election
  - Role: Director
  source text: On April 22, 2025, Mark D. Stolper, a member of the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), notified the Board of his intention not to stand for re-election to the Board for an additional three-year term at the Company's 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837025005554/0001558370-25-005554-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.